SCHEMBL6002543

SCHEMBL6002543

O=Cc1ccc(OCCN2c3ccccc3Oc3ccccc32)cc1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 2/20 0.53
PPARG P37231 1/20 0.53
PPARD Q03181 1/20 0.46
CACNA1H O95180 2/20 0.43
CACNA1B Q00975 2/20 0.43
ALDH1A1 P00352 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
HPGD P15428 2/20 0.42
LMNA P02545 2/20 0.42
MAPT P10636 1/20 0.42
ACHE P22303 2/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
NPSR1 Q6W5P4 1/20 0.40
KDM4E B2RXH2 1/20 0.40
RAB9A P51151 3/20 0.40
NPC1 O15118 1/20 0.40
SMPD1 P17405 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alcohol SCHEMBL7257570 0.94 PPARA (0.56) PPARAPPARGPPARDCACNA1HCACNA1B
SCHEMBL5107272 0.82 L3MBTL1 (0.51) ALDH1A1MAPTMEN1KMT2AKDM4E
SCHEMBL14501318 0.81 HPGD (0.46) PPARAPPARGALDH1A1SMN1; SMN2HPGD
SCHEMBL5427760 0.81 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2HPGDLMNAMAPT
SCHEMBL5606815 0.81 PPARG (0.45) PPARGALDH1A1SMN1; SMN2HPGDLMNA
SCHEMBL8120013 0.79 HPGD (0.60) HPGD
SCHEMBL8202466 0.78 HDAC3 (0.43) ALDH1A1SMN1; SMN2HPGDLMNAMAPT
SCHEMBL8134316 0.77 ACHE (0.45) PPARAPPARGPPARDHPGDACHE
SCHEMBL6004647 0.77 PPARA (0.57) PPARAPPARGPPARDCACNA1HCACNA1B
SCHEMBL7249198 0.77 PPARA (0.55) PPARAPPARGPPARDCACNA1HCACNA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119198-B2 Tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them DR. REDDY'S RESEARCH FOUNDATION (IN) 2006-10-10 US disclosed
US-20060148793-A1 Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them REDDYS'S RESEARCH FOUNDATION 2006-07-06 US disclosed
US-6939988-B1 Tricyclic compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them DR. REDDY'S LABORATORIES LIMITED (IN) 2005-09-06 US disclosed
US-6608194-B1 Hypolipidemic, antihyperglycemic, antiobesity and hypocholes-terolemic agents DR. REDDY'S LABORATORIES LIMITED (IN) 2003-08-19 US disclosed
US-6548666-B1 Phenazine, phenoxazine, or phenothiazine derivatives; antilipemic, hypoglycemic, anticholesterol and antiobesity agents DR. REDDY'S RESEARCH FOUNDATION (IN) 2003-04-15 US disclosed
WO-2003008397-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF ANTIDIABETIC PHENOXAZINE COMPOUNDS DR. REDDY'S LABORATORIES LTD. (IN) 2003-01-30 WO disclosed
US-6440961-B1 Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them DR. REDDY'S RESEARCH FOUNDATION (IN) 2002-08-27 US disclosed
US-20020077320-A1 Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them DR. REDDY'S RESEARCH FOUNDATION AND REDDY- CHEMINOR, INC. 2002-06-20 US disclosed
EP-1155006-A1 NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE; PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM Dr. Reddy's Research Foundation (IN) 2001-11-21 EP disclosed
US-6159966-A Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them REDDY-CHEMINOR INC. (US) 2000-12-12 US disclosed
EP-1049684-A1 NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE; PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DR. REDDY'S RESEARCH FOUNDATION (IN) 2000-11-08 EP disclosed
WO-2000050414-A1 NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE; PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM DR.REDDY'S RESEARCH FOUNDATION (IN) 2000-08-31 WO disclosed
US-6054453-A HYPOLIPIDEMIC, ANTIHYPERGLYCEMIC USES. REDD'S RESEARCH FOUNDATION (IN) 2000-04-25 US disclosed
EP-0977753-A1 AZOLIDINEDIONES USEFUL FOR THE TREATMENT OF DIABETES, DYSLIPIDEMIA AND HYPERTENSION DR. REDDY'S RESEARCH FOUNDATION (IN) 2000-02-09 EP disclosed
US-6011031-A Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them DR. REDDY'S RESEARCH FOUNDATION (IN) 2000-01-04 US disclosed
WO-1999019313-A1 NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE; PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DR. REDDY'S RESEARCH FOUNDATION (IN) 1999-04-22 WO disclosed
WO-1998052946-A1 AZOLIDINEDIONES USEFUL FOR THE TREATMENT OF DIABETES, DYSLIPIDEMIA AND HYPERTENSION DR. REDDY'S RESEARCH FOUNDATION (IN) 1998-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020077320-A1 Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them LIPC, GPR119, CPT1A PPARA 281/4885PPARG 102/4885PPARD 308/4885
US-20060148793-A1 Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them LIPC, GPR119, CPT1A PPARA 209/4885PPARG 73/4885PPARD 235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.